Skip to main content

Overview

Investor Contacts

Chris Lewis
Vice President, Investor Relations & Corporate Affairs

949-503-4346
investors@glaukos.com

Investor Email Alerts

Personal Information.

Email Address *Required Email Address is required. Email Address is invalid.

Investor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote
Events & Presentations

Investor Alert Options is required.

The captcha test has failed. Please try again.

focus areas

Cornea opens in new window
Glaucoma opens in new window
Retina opens in new window

company

About Us opens in new window
Innovation opens in new window
Executive Team opens in new window
Board of Directors opens in new window
Our History opens in new window
Global Charity opens in new window
Awards & Recognitions opens in new window

Careers

Life at Glaukos opens in new window
Talent Acquisition opens in new window

Investors

Financials & Filings opens in new window
Corporate Governance opens in new window
Press Releases opens in new window
Events & Presentations opens in new window
Resources & Alerts opens in new window

Policies & Info

Terms of Use opens in new window
Privacy Policy opens in new window
Privacy Request Form opens in new window
Declaration of Compliance opens in new window
Patents opens in new window
Patient Resources opens in new window
Prescribing Information opens in new window

©2026 Glaukos Corporation. All rights reserved.
Glaukos, Transforming Vision, iDose, iStent, iStent inject, iStent inject W, iStent infinite, and iAccess are registered trademarks of Glaukos Corporation. The KXL system is a registered trademark of Avedro, a Glaukos company. Mitosol is a registered trademark of Mobius Therapeutics, a Glaukos company. PM-US-3180-1